Aclaris Therapeutics, Inc.

Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases. Its core engine is the KINect drug discovery platform, which it uses to generate product candidates with differentiated target affinity, specificity, and potency. The company is still in development mode and does not have commercial product sales from its own pipeline; instead, it seeks partnerships and other transactions to advance, approve, and potentially commercialize its assets. Aclaris also earns revenue from contract research services and from licensing arrangements tied to partnered assets.

−970,1 %

73,3 %

−829,6 %

−58,2 %

3.36

— Aclaris Therapeutics, Inc.
	%
Therapeutics pipeline	70% Clinical and preclinical drug candidates for immuno-inflammatory diseases, including antibodies and small molecules.
Contract research services	20% Laboratory services provided to third parties using the company’s research and development capabilities.
Licensing and partnering revenue	10% Upfront, milestone, and royalty income from out-licensed assets and collaboration agreements.

Aclaris’s primary customers are not end patients today, but pharmaceutical and biotechnology partners that license or...

Strategic pharma and biotech partnersprimary
License or co-develop bosakitug, ATI-052, lepzacitinib, and other assets to gain access to differentiated immunology programs and development rights.
Contract research clientssecondary
Purchase laboratory and research services because Aclaris can monetize its scientific capabilities while its internal pipeline remains pre-commercial.
Future commercial end usersemerging
Physicians, payors, and patients would be the eventual buyers of approved therapies, especially in dermatology and immuno-inflammatory indications.

Aclaris is headquartered in the United States and conducts its core research and corporate activities there...

•United States is the company’s home market and operating base
•No owned manufacturing facilities; supply is outsourced to third parties
•Greater China is a licensed territory for lepzacitinib via Pediatrix
•Global partnering is part of the commercialization strategy
•Geographic exposure is driven by partner territories and regulatory markets

Aclaris is focused on advancing a pipeline of immuno-inflammatory therapies while preserving capital through...

Partner and monetize pipeline assetsshort-term

Aclaris needs external capital and commercialization capability to move programs forward without bearing the full cost alone.

Advance lead immunology programsmedium-term

Clinical progress is necessary to create partnering value and eventual approval potential.

Preserve capital and extend runwayshort-term

The company expects continued operating losses and needs funding to sustain R&D.

Aclaris faces the classic risks of a clinical-stage biotech company: high R&D burn, uncertain clinical outcomes, and...

high

Clinical development failure

Pipeline value depends on positive trial outcomes, but immunology programs can fail on efficacy, safety, or endpoint design.

Scope: bosakitug, ATI-052, lepzacitinib, ATI-2138, ATI-9494
Materiality: high

high

Dependence on third-party data and partners

Aclaris in-licenses assets and relies on external parties for trials, manufacturing, and some commercialization activities, so errors outside its control can impair programs.

Scope: Biosion-origin programs, CROs, CMOs, Pediatrix, Sun Pharma
Materiality: high

high

Financing and dilution risk

The company expects continued losses and will need additional capital or partnering proceeds to sustain development.

Scope: Corporate funding and pipeline advancement
Materiality: high

medium

Competitive pressure in immunology

Large pharma and biotech competitors are developing similar TSLP and cytokine-pathway therapies, which can reduce market opportunity and partnering leverage.

Scope: bosakitug, ATI-052
Materiality: medium

medium

Manufacturing and supply chain dependence

The company has no manufacturing facilities and depends on third parties for clinical and preclinical supply.

Scope: All product candidates
Materiality: medium

Licensing revenue recognition

Affects reported revenue timing and comparability across periods

Contract research revenue

Drives volatility in the contract research segment

Non-cash royalty income

Affects other income and earnings quality

Contingent consideration and in-process R&D

Can materially affect R&D expense and balance sheet estimates

Aclaris Therapeutics, Inc.

Clinical development failure

Dependence on third-party data and partners

Financing and dilution risk

Competitive pressure in immunology

Manufacturing and supply chain dependence

NEKTAR THERAPEUTICS

Monopar Therapeutics

Acrivon Therapeutics, Inc.

Kezar Life Sciences, Inc.

Kiniksa Pharmaceuticals International, plc

Actinium Pharmaceuticals, Inc.